SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

approvedPositive

AI Analysis

Summary

SciSparc's subsidiary NeuroThera Labs completed the acquisition of approximately 54% interest in CliniQuantum Ltd., a move that expands NeuroThera's portfolio in central nervous system disorder treatments.

Outcome Details

NeuroThera Labs completed acquisition of approximately 54% interest in CliniQuantum Ltd.

Importance:6/10

Sentiment:

0.50

acquisitionM&AsubsidiaryCNS focus

Related Companies

$SPRC $NTLX

Read the original article

Published by GlobeNewswire Pharma on June 4, 2026 11:32 AM

Read Original